Showing results (211-220 of 280) with videos related to
Sort By:
Pageof 28
The World Journal of Men'S Health|September 1, 2022
Initial Longitudinal Outcomes of Risk-Stratified Men in Their Forties Screened for Prostate Cancer Following Implementation of a Baseline Prostate-Specific AntigenZoe D Michael, Srinath Kotamarti, Rohith Arcot, et al.European Urology Oncology|February 18, 2020
Phase II Trial of Enzalutamide and Androgen Deprivation Therapy with Salvage Radiation in Men with High-risk Prostate-specific Antigen Recurrent Prostate Cancer: The STREAM TrialRhonda L Bitting, Patrick Healy, Daniel J George, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2019
PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUNAbdallah Flaifel, Wanling Xie, David A Braun, et al.JAMA|June 8, 2006
Sunitinib in patients with metastatic renal cell carcinomaRobert J Motzer, Brian I Rini, Ronald M Bukowski, et al.Genes, Chromosomes & Cancer|November 10, 2019
Discordant and heterogeneous clinically relevant genomic alterations in circulating tumor cells vs plasma DNA from men with metastatic castration resistant prostate cancerSantosh Gupta, Daniel H Hovelson, Gabor Kemeny, et al.Journal for Immunotherapy of Cancer|March 3, 2021
LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer typesLandon C Brown, Matthew D Tucker, Ramy Sedhom, et al.Clinical Genitourinary Cancer|February 9, 2022
Establishing metastatic prostate cancer quality indicators using a modified Delphi approachJia Zheng, Fanny Sampurno, Daniel J George, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 7, 2005
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinomaRobert J Motzer, M Dror Michaelson, Bruce G Redman, et al.Prostate Cancer and Prostatic Diseases|March 11, 2022
A randomized controlled trial comparing changes in fitness with or without supervised exercise in patients initiated on enzalutamide and androgen deprivation therapy for non-metastatic castration-sensitive prostate cancer (EXTEND)Michael R Harrison, Paul G Davis, Michel G Khouri, et al.Biomarker Research|November 4, 2021
Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinomaMatthew D Tucker, Landon C Brown, Yu-Wei Chen, et al.Pageof 28